murine MAb against human uPAR
Description
The monoclonal antibody ADG3937 (clone HD-UPAR-13.1.1) is a murine monoclonal antibody, subclass IgG1 recognizing the human urokinase receptor (uPAR) domain 2+3. It binds with high affinity to both uPAR and uPA/uPAR complexes.
Properties
ADG3937 is non-inhibitory, it does not block uPA from binding to uPAR. Pre-incubation with various uPAR preparations (CHO cell line, U937 cells) can completely inhibit binding of ADG3937 to uPAR). Cross-reactivity with uPAR from other species has not been determined.
Presentation
Screw capped vial containing 250 µg of purified antibody in PBS pH 7.4, 0.01 % ProClin300. The IgG concentration is 1 mg/ml. Spin the vial briefly before opening.
Storage and Stability
Store the antibody at 2°-8°C. For long-term storage the antibody should be aliquoted and stored at –20°C or colder. It is recommended to avoid freeze-thaw cycles.
Applications
A. Immunohistochemical/Flow Cytometry Analysis
ADG3937 is suitable for staining of formalin-fixed, paraffin-embedded tissue sections. The antibody stains both fresh frozen and formalin-fixed PMA stimulated U937 cells for flow cytometry. A 1:100 dilution (10 μg/mL concentration) is recommended.
B. Immunoprecipitation of uPAR
Using a 5:1 molar ratio, ADG3937 precipitates various uPAR preparations, showing a broad band between 39-66 kDa per an SDS-gel electro-phoresis, owing to the extensive glycosylations of the preparations (N-linked type). Enzymatic deglycosylation reduces this broad band to a single, sharp 29 kDa band.
C. Western Blot Analysis
ADG3937 is suitable for use in Western blot analysis. Under non-reducing conditions, 2 μg/mL of ADG3937 can visualize as little as 50 ng of uPAR.
Category: Research use only
Type: Antibody
Product Availability: Worldwide
Manufacturer: ImmBioMed GmbH & Co KG, Germany
For more information please click .pdf icon below.
murine MAb against human uPAR, clone HD-UPAR-13.1
Cat.No. ADG3937
Article no.: 938132
Unit: 250 µg
Code: ADG3937
Manufacturer: ImmBioMed GmbH & Co. KG
References
- Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Beyer et al., Cancer. 2006 Mar 1;106(5):1026-1035.
- uPA-Silica-Particles (SP-uPA): A Novel Analytical System to Investigate uPA-uPAR Interaction and to Test Synthetic uPAR Antagonists as Potential Cancer Therapeutics. Guthaus et al., 2002, Biol. Chem., Vol. 383, pp. 207–216.
- Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. Ferrier CM et al., J Histochem Cytochem. 1998 Apr;46(4):469-476.
- Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocyto-chemistry. Kennedy et al., Br J Cancer. 1998 May; 77(10): 1638–1641.
- Dispase-Mediated Basal Detachment of Cultured Keratinocytes Induces Urokinase-type Plasminogen Activator (uPA) and Its Receptor (uPA-R, CD87). Schaefer et al., 1996, Exp Cell Res 228, 246–253.
- Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1b and Tumor Necrosis Factor-a. Bechtel et al., 1996. Exp Cell Res 223, 395–404.